U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07490236) titled 'Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors' on Feb. 25.
Brief Summary: Trilaciclib, an innovative first-in-class therapy that protects bone marrow at the source, has been approved for use in CDK4/6-independent small-cell lung cancer. However, clinical practice shows that patients with solid tumors frequently experience treatment-related pancytopenia involving neutrophils, erythroid lineage, and platelets after antineoplastic therapy, with a particularly high incidence of grade 3-4 myelosuppression. This poses serious threats to patient safety and delays the timely, standard administr...